M Mulder1,2, D Radjabzadeh3, J C Kiefte-de Jong1,4, A G Uitterlinden1,3, R Kraaij3, B H Stricker1,2,3, A Verbon3,5. 1. Department of Epidemiology , Erasmus MC, Rotterdam, The Netherlands. 2. Youth and Healthcare Inspectorate , Heerlen, The Netherlands. 3. Department of Internal Medicine , Erasmus MC, Rotterdam, The Netherlands. 4. Department of Public Health and Primary Care, LUMC, The Hague , The Netherlands. 5. Department of Medical Microbiology and Infectious Diseases , Erasmus MC, Rotterdam, The Netherlands.
Abstract
INTRODUCTION: Antimicrobial drugs are known to have effects on the human gut microbiota. We studied the long-term temporal relationship between several antimicrobial drug groups and the composition of the human gut microbiota determined in feces samples. METHODS: Feces samples were obtained from a community-dwelling cohort of middle-aged and elderly individuals (Rotterdam Study). Bacterial DNA was isolated and sequenced using V3/V4 16 S ribosomal RNA sequencing (Illumina MiSeq). The time between the last prescription of several antimicrobial drug groups and the day of sampling was categorized into 0-12, 12-24, 24-48 and >48 months. The effects of the antimicrobial drug groups on the Shannon alpha-diversity (diversity), the Bray-Curtis beta-diversity (community structure), the Firmicutes/Bacteroidetes (F/B) ratio and individual genera were determined. RESULTS: We studied the gut microbiota of 1413 individuals (57.5% female, median age 62.6 years). The alpha-diversity was significantly lower up to 4 years after prescriptions of macrolides and lincosamides. It was also lower in the first year after the use of beta-lactams. The community structure (beta-diversity) of the microbiota was significantly different up to 4 years for macrolides and lincosamides, the first year for beta-lactams and at least the first year for quinolones. For the F/B ratio, drugs with a high anaerobic activity shifted the ratio toward Firmicutes in the first year whereas other antimicrobial drugs shifted the ratio toward Bacteroidetes. CONCLUSION: Use of antimicrobial drugs is associated with a shift in the composition of the gut microbiota.These effects differ in strength and duration, depending on the antimicrobial drug group used. These findings should be considered when prescribing antimicrobial drugs.
INTRODUCTION: Antimicrobial drugs are known to have effects on the human gut microbiota. We studied the long-term temporal relationship between several antimicrobial drug groups and the composition of the human gut microbiota determined in feces samples. METHODS: Feces samples were obtained from a community-dwelling cohort of middle-aged and elderly individuals (Rotterdam Study). Bacterial DNA was isolated and sequenced using V3/V4 16 S ribosomal RNA sequencing (Illumina MiSeq). The time between the last prescription of several antimicrobial drug groups and the day of sampling was categorized into 0-12, 12-24, 24-48 and >48 months. The effects of the antimicrobial drug groups on the Shannon alpha-diversity (diversity), the Bray-Curtis beta-diversity (community structure), the Firmicutes/Bacteroidetes (F/B) ratio and individual genera were determined. RESULTS: We studied the gut microbiota of 1413 individuals (57.5% female, median age 62.6 years). The alpha-diversity was significantly lower up to 4 years after prescriptions of macrolides and lincosamides. It was also lower in the first year after the use of beta-lactams. The community structure (beta-diversity) of the microbiota was significantly different up to 4 years for macrolides and lincosamides, the first year for beta-lactams and at least the first year for quinolones. For the F/B ratio, drugs with a high anaerobic activity shifted the ratio toward Firmicutes in the first year whereas other antimicrobial drugs shifted the ratio toward Bacteroidetes. CONCLUSION: Use of antimicrobial drugs is associated with a shift in the composition of the gut microbiota.These effects differ in strength and duration, depending on the antimicrobial drug group used. These findings should be considered when prescribing antimicrobial drugs.
Entities:
Keywords:
Gut microbiota; antimicrobial use; beta-lactams; macrolides and lincosamides; nitrofuran derivatives; quinolones; sulfonamides and trimethoprim; tetracyclines
Authors: M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman Journal: Eur J Epidemiol Date: 2017-10-24 Impact factor: 8.082
Authors: Gijs den Besten; Karen van Eunen; Albert K Groen; Koen Venema; Dirk-Jan Reijngoud; Barbara M Bakker Journal: J Lipid Res Date: 2013-07-02 Impact factor: 5.922
Authors: Carlo Bressa; María Bailén-Andrino; Jennifer Pérez-Santiago; Rocío González-Soltero; Margarita Pérez; Maria Gregoria Montalvo-Lominchar; Jose Luis Maté-Muñoz; Raúl Domínguez; Diego Moreno; Mar Larrosa Journal: PLoS One Date: 2017-02-10 Impact factor: 3.240
Authors: Trudy Voortman; Jessica C Kiefte-de Jong; M Arfan Ikram; Bruno H Stricker; Frank J A van Rooij; Lies Lahousse; Henning Tiemeier; Guy G Brusselle; Oscar H Franco; Josje D Schoufour Journal: Eur J Epidemiol Date: 2017-08-19 Impact factor: 8.082
Authors: Evangelia M Stavroulaki; Jan S Suchodolski; Rachel Pilla; Geoffrey T Fosgate; Chi-Hsuan Sung; Jonathan A Lidbury; Jörg M Steiner; Panagiotis G Xenoulis Journal: PLoS One Date: 2021-12-15 Impact factor: 3.240